NCIL intends to utilise net proceeds from the IPO to set up a multi-speciality hospital ‘Vivacity Multi Speciality Hospital’ at Madhyamgaram in Kolkata, West Bengal, and for general corporate purposes
Kolkata-based Nephro Care India Ltd (NCIL) announced the filing of its Draft Red Herring Prospectus (DRHP) with NSE Emerge. The company’s initial public offering comprises a fresh issuance of 45,84,000 equity shares, each with a face value of Rs 10.
Corporate Capital Ventures is the sole Book Running Lead Manager to the Issue, and Bigshare Services is the Registrar. Corporate Capital Ventures has completed a string of successful SME IPOs in recent months, including Trust Fintech, Creative Graphics, Alpex Solar, Rockingdeals, Accent Microcell, Oriana Power, Droneacharya and Crayons Advertising, among others.
In December 2023, Nephro Care India Limited successfully closed the pre-IPO funding round, which saw the participation of banking veteran and former chairman of HDFC, Deepak Parekh, Chairman, HDFC Securities Bharat Shah, and Rajendra Agarwal, Founder and MD of Macleods Pharmaceuticals, among others.
The healthcare provider offers a wide range of clinical and lifestyle solutions and renal insufficiency treatment to patients. The treatment framework at NCIL covers the entire range of lifestyle, physiological and spiritual aspects of wellness.
The company is also in the process of opening three more satellite clinics at Alipurduar and Shyambazar in West Bengal and Balasore in Odisha.
According to DRHP, NCIL intends to utilise net proceeds from the IPO to set up a multi-speciality hospital, ‘Vivacity Multi Speciality Hospital’, at Madhyamgaram in Kolkata, West Bengal, and for general corporate purposes. The new hospital will be a unit of Nephro Care India and is proposed to include 100 inpatient beds, including a 30-bed critical care unit having ICU, HDU, RTU and NICU facilities. Vivacity will offer treatment services in various disciplines such as cardiology, medical oncology, gastroenterology, gynaecology and many others, including an advanced renal transplant unit in East India.
NCIL’s clinics are operated on a ‘hub-and-spoke’ model, where each clinic is independent and individually well-equipped with skilled healthcare professionals and advanced infrastructure to serve the healthcare needs of the patients and ensure their rehabilitation.
NCIL posted a revenue of Rs 19.90 crore and earned a profit (PAT) of Rs 3.4 crore during the first nine months of FY 2023-24, compared to a revenue of Rs 17.09 crore, with a profit (PAT) of Rs 1.94 crore in FY 2022-23.
